Prevalence of Generalized Anxiety Disorder in Psychiatric Outpatients: A Multi-center Cross-sectional Study in Japan (PRADO study)

Viatris Pharmaceuticals Japan G.K.0 个研究点目标入组 400 人开始时间: 2024年5月8日最近更新: 2025年4月14日

适应症

试验速览

暂无简介。

•Patients fulfilling all the following criteria will be enrolled in the study:
•Patients aged more than or equal to 18 years to less than 80 years at the time of signing the informed consent form.
•Patients who are outpatients at a psychiatrist department except for the first visit.
•Patients with a principal diagnosis of ICD-10 Code F30-F39 mood (affective) disorders or F40-F4 neurotic, stress-related, and somatoform disorders.
•Patients with written consent and are willing to participate in the study

•Ptients will be excluded from the study if any of the following criteria apply:
•Participants who meet the following based on the applicable ICD-10 category.
•a. Patients with mental and behavioral disorders due to psychoactive substance use or diagnosed as addictive within 12-months prior to the start of the study.
•b. Patients with a current or past medical history of schizophrenia, delusional disorder, or other
•psychotic disorders.
•c. Patients currently having dementia.
•d. Patients with mood disorder or anxiety disorder due to known physiological conditions.
•Patients with a history of convulsive disease other than single febrile seizures in childhood.
•Patients judged to be at risk of suicide by the investigator.
•Patients who are considered inappropriate to participate in the study by the investigator

Prevalence of Generalized Anxiety Disorder

To estimate the prevalence of patients diagnosed with Generalized Anxiety Disorder based on DSM-5 diagnostic criteria, which is confirmed by SCID.

发起方

Viatris Pharmaceuticals Japan G.K.